Mr. Fengmin Xi joined InxMed in March 2023 as DMPK Director. Fengmin has more than 10 years of R&D experience in DMPK, toxicology, and medicinal chemistry, additionally, along with rich investment and financing skills in biotechnology. He was previously employed in a biotech boutique investment bank, HollyHigh, and engaged in investment and financing for biotech and CXO companies. Prior to that, he worked for WuXi AppTec (603259. SH/2359.HK) and Medicilon (688202. SH) in clinical bioanalysis, preclinical DMPK, and toxicology. He held a Ph.D. in medicinal chemistry at Peking Union Medical College and Tsinghua University.